On Dec 24, the Huangpu Biomedical Device Registration Guidance Service Station started operations. The station is the first of its kind in Guangdong province.
It will provide end-to-end services, establish a team of technical experts, strengthen the coordination between review and inspection resources, and offer professional technical services for enterprises throughout the review and approval process.
To improve service mechanisms, the Huangpu district market supervision bureau has established a new drug declaration service center and formed a team with experience in provincial-level reviews, inspections, and testing to provide technical services for the biopharmaceutical industry.
Huangpu biomedical industry talent team. [Photo/WeChat account: guangzhougaoxinqu]
The establishment of the Huangpu Service Station will expedite the product listing process and provide strong support for innovation and entrepreneurship in the biopharmaceutical talent sector.
The biopharmaceutical industry in Huangpu is flourishing. With nearly 100 new drug clinical trial approvals issued annually for three consecutive years, the most in the province, and a total of eight approved innovative drugs, Huangpu leads the province in numbers.
Huangpu has attracted over 4,800 biopharmaceutical companies, including 20 publicly listed companies, with an industrial revenue scale of 230 billion yuan ($31.51 billion). It has been awarded the title of Best Biomedical Park in China, placing it at the forefront of domestic biopharmaceutical industry development.